A novel tripartite STAT5B::RARA::RP11-750B16.1 fusion in variant acute promyelocytic leukemia. Comment on: "Novel ligand-binding domain truncated CPSF7::RARA::CPSF7 tripartite fusion confers primary ATRA resistance in atypical acute promyelocytic leukemia"

Key Points

• This commentary discusses a new genetic fusion associated with variant acute promyelocytic leukemia and its implications for treatment resistance.
• Commentary on existing research regarding the STAT5B::RARA::RP11-750B16.1 fusion and its clinical impact.
• Analysis of the relationship between gene fusions and treatment resistance in acute promyelocytic leukemia.
• Highlights the significance of the STAT5B::RARA::RP11-750B16.1 fusion in variant cases of acute promyelocytic leukemia.
• Emphasizes potential challenges in treatment due to ATRA resistance linked to specific fusions.